Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTJCPUT)

• DTT Name: Coagulation factor XI (F11) DTT Info
• Gene Name: F11

Molecule-Related Drug & Molecule List

7 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
A186	DMHJ0EB	Clotting disorder	3B4Z	IND submitted	[1]
Asundexian	DMLZMU2	Ischemic stroke	8B11.5Z	Phase 3	[2]
Abelacimab	DM09YTN	Atrial fibrillation	BC81.3	Phase 2	[3]
MK-2060	DM79A32	Thrombosis	DB61-GB90	Phase 2	[4]
A336	DMVQG8G	Clotting disorder	3B4Z	Phase 1	[1]
AB023	DMBG9HI	End-stage renal disease	GB61.5	Phase 1	[5]
EP-7041	DMV0MHI	Thrombosis	DB61-GB90	Phase 1	[6]

References

• [1] Clinical pipeline report, company report or official report of Klus Pharma
• [2] Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa. J Thromb Haemost. 2022 Jun;20(6):1400-1411.
• [3] Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa. J Thromb Haemost. 2022 Feb;20(2):307-315.
• [4] Clinical pipeline report, company report or official report of MSD
• [5] Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial. Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):799-809.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)